ATE528015T1 - Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür - Google Patents

Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür

Info

Publication number
ATE528015T1
ATE528015T1 AT03726007T AT03726007T ATE528015T1 AT E528015 T1 ATE528015 T1 AT E528015T1 AT 03726007 T AT03726007 T AT 03726007T AT 03726007 T AT03726007 T AT 03726007T AT E528015 T1 ATE528015 T1 AT E528015T1
Authority
AT
Austria
Prior art keywords
methods
mammal
endothelial cells
prolifering
application
Prior art date
Application number
AT03726007T
Other languages
English (en)
Inventor
Ralph Reisfeld
Andreas Niethammer
Rong Xiang
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE528015T1 publication Critical patent/ATE528015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03726007T 2002-03-02 2003-02-28 Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür ATE528015T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/090,183 US7094410B2 (en) 2002-03-02 2002-03-02 DNA vaccine against proliferating endothelial cells and methods of use thereof
PCT/US2003/006256 WO2003073995A2 (en) 2002-03-02 2003-02-28 Dna vaccine against proliferating endothelial cells and methods of use thereof.

Publications (1)

Publication Number Publication Date
ATE528015T1 true ATE528015T1 (de) 2011-10-15

Family

ID=27787599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726007T ATE528015T1 (de) 2002-03-02 2003-02-28 Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür

Country Status (19)

Country Link
US (3) US7094410B2 (de)
EP (1) EP1487482B1 (de)
JP (1) JP4598401B2 (de)
KR (1) KR100979898B1 (de)
CN (1) CN1293917C (de)
AT (1) ATE528015T1 (de)
AU (1) AU2003228229B2 (de)
BR (1) BRPI0308103B8 (de)
CA (1) CA2477406C (de)
CY (1) CY1112663T1 (de)
DK (1) DK1487482T3 (de)
ES (1) ES2371870T3 (de)
MX (1) MXPA04008468A (de)
PL (1) PL213364B1 (de)
PT (1) PT1487482E (de)
RU (1) RU2318019C2 (de)
SI (1) SI1487482T1 (de)
WO (1) WO2003073995A2 (de)
ZA (1) ZA200406988B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1595548A3 (de) * 2001-03-07 2006-02-22 Mannkind Corporation Anti-Neovaskulatur Präparationen zur Krebsbehandlung
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
KR100614220B1 (ko) 2004-11-08 2006-08-21 고려대학교 산학협력단 Ｆｌｔ3 리간드 유전자를 발현하는 살모넬라 균주 및 이를함유하는 항암 치료용 조성물
CN101766818B (zh) * 2008-12-30 2013-05-22 陕西北美基因股份有限公司 多糖金磁复合微粒载药体及其制备方法
WO2010102140A1 (en) 2009-03-04 2010-09-10 The Trustees Of The University Of Pennsylvania Compositions comprising angiogenic factors and methods of use thereof
US9492523B2 (en) 2011-12-09 2016-11-15 The Board Of Regents For Oklahoma State University Broadly protective Shigella vaccine based on type III secretion apparatus proteins
JP6251179B2 (ja) * 2011-12-22 2017-12-20 バクシム アクチェンゲゼルシャフト 弱毒化サルモネラ株を高収量で生産する方法
WO2014005683A1 (en) 2012-07-05 2014-01-09 Vaximm Ag Dna vaccine for use in pancreatic cancer patients
KR102205077B1 (ko) 2012-08-31 2021-01-20 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｖｅｇｆ-특이적 에피토프 및/또는 안지오포이에틴-2-특이적 에피토프를 함유하는 ｄｎａ 백신
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
US9950053B2 (en) 2012-10-22 2018-04-24 The Board Of Regents For Oklahoma State University Use of the Salmonella SPP type III secretion proteins as a protective vaccination
ES2760699T3 (es) 2015-06-18 2020-05-14 Vaximm Ag Vacuna de ADN dirigida al VEGFR-2 para terapia de combinación
US20180153976A1 (en) 2015-06-18 2018-06-07 Vaximm Ag Novel cmv pp65 targeting dna vaccine for cancer immunotherapy
RU2759227C2 (ru) * 2020-04-10 2021-11-11 Генетик Диагностикс Энд Терапи 21 Лтд ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214804B1 (en) * 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US6228844B1 (en) * 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
DE69735292T2 (de) * 1996-10-25 2006-10-19 Gilead Sciences, Inc., Foster City Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe
WO1998058053A1 (en) * 1997-06-18 1998-12-23 Merck & Co., Inc. Human receptor tyrosine kinase, kdr
EP1032583A4 (de) * 1998-03-06 2005-02-02 Imclone Systems Inc Aktive immunisierung gegen durch angiogenese hervorgerufene antigene
DK1108035T3 (da) * 1998-09-04 2007-09-24 Sanofi Pasteur Ltd Behandling af cervixcancer
WO2002003961A1 (en) 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
US7094410B2 (en) * 2002-03-02 2006-08-22 The Scripps Research Institute DNA vaccine against proliferating endothelial cells and methods of use thereof

Also Published As

Publication number Publication date
WO2003073995A2 (en) 2003-09-12
ES2371870T3 (es) 2012-01-10
EP1487482B1 (de) 2011-10-12
AU2003228229A1 (en) 2003-09-16
ZA200406988B (en) 2005-11-30
RU2004129332A (ru) 2005-05-27
US8048428B2 (en) 2011-11-01
SI1487482T1 (sl) 2012-01-31
BRPI0308103B8 (pt) 2021-05-25
US20120039931A1 (en) 2012-02-16
WO2003073995A3 (en) 2003-11-20
BR0308103A (pt) 2005-01-04
BRPI0308103B1 (pt) 2019-02-19
CA2477406C (en) 2013-10-29
KR20040088573A (ko) 2004-10-16
US8241637B2 (en) 2012-08-14
JP2005519092A (ja) 2005-06-30
US20030185802A1 (en) 2003-10-02
RU2318019C2 (ru) 2008-02-27
US20070059323A1 (en) 2007-03-15
CY1112663T1 (el) 2016-02-10
CA2477406A1 (en) 2003-09-12
CN1293917C (zh) 2007-01-10
MXPA04008468A (es) 2004-12-06
PL372314A1 (en) 2005-07-11
PL213364B1 (pl) 2013-02-28
PT1487482E (pt) 2011-12-29
US7094410B2 (en) 2006-08-22
CN1649622A (zh) 2005-08-03
AU2003228229B2 (en) 2008-03-06
KR100979898B1 (ko) 2010-09-06
DK1487482T3 (da) 2011-12-05
JP4598401B2 (ja) 2010-12-15
EP1487482A4 (de) 2006-04-12
EP1487482A2 (de) 2004-12-22

Similar Documents

Publication Publication Date Title
EP1487482A4 (de) Dna-vakzine gegen proliferierende endothelzellen und anwendungsverfahren dafür
IS6750A (is) Samrunnin heterósýklísk súkkínímíð efnasambönd oghliðstæður þeirra, stillar fyrir starfsemi kjarnahormónaviðtaka
AR074501A1 (es) Oligonucleotidos inmunoestimuladores
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
ATE514433T1 (de) Nucleotid und zelluläre vakzine-zusammensetzung
IL171966A0 (en) Prostate stem cell antigen variants and pharmaceutical compositions based thereon
FI1897548T4 (fi) T-solujen säätely
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
NZ605429A (en) Therapeutic human anti-il-1r1 monoclonal antibody
SE9800836D0 (sv) New Compounds
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
IL173078A0 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
DK1328547T3 (da) Identifikation og modifikation af immundominante epitoper i polypeptider
IL161832A0 (en) Pharmaceutical composition for inducing an immune response in a human or animal
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
SG160424A1 (en) Compositions of influenza viral proteins and methods of use thereof
WO2002088328A3 (en) Method for generating highly active human dendritic cells from monocytes
WO2004012681A3 (en) Cancer vaccines containing epitopes of oncofetal antigen
EE200100366A (et) Antikehade kasutamine vähivastase farmatseutilisekompositsiooni valmistamiseks
BR0207528A (pt) Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
DE50006420D1 (de) Zyklische peptidomimetische urokinaserezeptorantagonisten
NO20053328D0 (no) Immunisering av fisk med uttrykte proteiner i planteceller.
DE60109922D1 (de) Therapeutische verbindungen gegen eierstockkrebs
WO2005077048A3 (en) Immune modulation by regulating expression of the “minor” gene in immune dendritic cells
ATE555124T1 (de) Nukleinsäuren und entsprechende proteine 58p1d12 zum nachweis von krebs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1487482

Country of ref document: EP